{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T01:15:40Z","timestamp":1728177340082},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,16]]},"DOI":"10.7759\/cureus.41951","type":"journal-article","created":{"date-parts":[[2023,7,16]],"date-time":"2023-07-16T13:31:31Z","timestamp":1689514291000},"source":"Crossref","is-referenced-by-count":1,"title":["New-Onset Polymyalgia Rheumatica Complicated by Giant Cell Arteritis Following COVID-19 Infection"],"prefix":"10.7759","author":[{"given":"Divya","family":"Mamootil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.08.009","article-title":"Glucocorticoids for management of polymyalgia rheumatica and giant cell arteritis","volume":"42","author":"Matteson EL","year":"2016","unstructured":"Matteson EL, Buttgereit F, Dejaco C, Dasgupta B. Glucocorticoids for management of polymyalgia rheumatica and giant cell arteritis. Rheum Dis Clin North Am. 2016, 42:75-90. 10.1016\/j.rdc.2015.08.009","journal-title":"Rheum Dis Clin North Am"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0458-5","article-title":"Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica","volume":"16","author":"Camellino D","year":"2020","unstructured":"Camellino D, Matteson EL, Buttgereit F, Dejaco C. Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica. Nat Rev Rheumatol. 2020, 16:481-495. 10.1038\/s41584-020-0458-5","journal-title":"Nat Rev Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21608","article-title":"A case of giant cell arteritis presenting after COVID-19 vaccination: is it just a coincidence?","volume":"14","author":"Greb CS","year":"2022","unstructured":"Greb CS, Aouhab Z, Sisbarro D, Panah E. A case of giant cell arteritis presenting after COVID-19 vaccination: is it just a coincidence?. Cureus. 2022, 14:e21608. 10.7759\/cureus.21608","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13525","article-title":"An update on polymyalgia rheumatica","volume":"292","author":"Lundberg IE","year":"2022","unstructured":"Lundberg IE, Sharma A, Turesson C, Mohammad AJ. An update on polymyalgia rheumatica. J Intern Med. 2022, 292:717-732. 10.1111\/joim.13525","journal-title":"J Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/art.42325","article-title":"2022 American College of Rheumatology\/EULAR Classification Criteria for giant cell arteritis","volume":"74","author":"Ponte C","year":"2022","unstructured":"Ponte C, Grayson PC, Robson JC, et al.. 2022 American College of Rheumatology\/EULAR Classification Criteria for giant cell arteritis. Arthritis Rheumatol. 2022, 74:1881-1889. 10.1002\/art.42325","journal-title":"Arthritis Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.10155","article-title":"Polymyalgia rheumatica and giant cell arteritis","volume":"324","author":"Buttgereit F","year":"2020","unstructured":"Buttgereit F, Matteson EL, Dejaco C. Polymyalgia rheumatica and giant cell arteritis. JAMA. 2020, 324:993-994. 10.1001\/jama.2020.10155","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone JH","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S, et al.. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017, 377:317-328. 10.1056\/NEJMoa1613849","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.15459","article-title":"Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial","volume":"328","author":"Devauchelle-Pensec V","year":"2022","unstructured":"Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, et al.. Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial. JAMA. 2022, 328:1053-1062. 10.1001\/jama.2022.15459","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/11795476221088472","article-title":"A case report of post COVID19 giant cell arteritis and polymyalgia rheumatica with visual loss","volume":"15","author":"Mursi AM","year":"2022","unstructured":"Mursi AM, Mirghani HO, Elbeialy AA. A case report of post COVID19 giant cell arteritis and polymyalgia rheumatica with visual loss. Clin Med Insights Case Rep. 2022, 15:11795476221088472. 10.1177\/11795476221088472","journal-title":"Clin Med Insights Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2020.11.005","article-title":"SARS-CoV-2 infection triggering a giant cell arteritis","volume":"156","author":"Riera-Mart\u00ed N","year":"2021","unstructured":"Riera-Mart\u00ed N, Roman\u00ed J, Calvet J. SARS-CoV-2 infection triggering a giant cell arteritis. Med Clin (Barc). 2021, 156:253-254. 10.1016\/j.medcli.2020.11.005","journal-title":"Med Clin (Barc)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/agm2.12171","article-title":"Polymyalgia rheumatica as uncommon adverse event following immunization with COVID-19 vaccine: a case report and review of literature","volume":"4","author":"Manzo C","year":"2021","unstructured":"Manzo C, Natale M, Castagna A. Polymyalgia rheumatica as uncommon adverse event following immunization with COVID-19 vaccine: a case report and review of literature. Aging Med (Milton). 2021, 4:234-238. 10.1002\/agm2.12171","journal-title":"Aging Med (Milton)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00106-5","article-title":"Incident systemic rheumatic disease following COVID-19","volume":"3","author":"Hsu TY","year":"2021","unstructured":"Hsu TY, D'Silva KM, Patel NJ, Fu X, Wallace ZS, Sparks JA. Incident systemic rheumatic disease following COVID-19. Lancet Rheumatol. 2021, 3:e402-e404. 10.1016\/S2665-9913(21)00106-5","journal-title":"Lancet Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/170325-new-onset-polymyalgia-rheumatica-complicated-by-giant-cell-arteritis-following-covid-19-infection","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:06:07Z","timestamp":1707509167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/170325-new-onset-polymyalgia-rheumatica-complicated-by-giant-cell-arteritis-following-covid-19-infection"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,16]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.41951","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,16]]}}}